Effect of Shenqi Fuzheng Liquid as Adjunctive Therapy on Inflammatory Factors and Cancer Pain in Patients with Lung Cancer

doi:10.16458/j.cnki.1007-0893.2025.12.017

Abstract：Objective: To investigate the effect of Shenqi Fuzheng Liquid as adjunctive therapy on inflammatory factors and cancer pain in patients with lung cancer. Methods: A total of 105 patients with lung cancer admitted to Zhengzhou Third People's Hospital from January 2022 to February 2024 were selected as the study subjects and randomly divided into a control group (52 cases) and an observation group (53 cases) according to the random number table method. Both groups received radical surgery for lung cancer. The control group received conventional chemotherapy, while the observation group received Shenqi Fuzheng Liquid as adjunctive therapy on top of the control group's treatment. The clinical efficacy, cancer pain scores and TCM syndrome scores before and after treatment, serum levels of inflammatory factors, incidence of adverse reactions, and serum levels of tumor markers before and after treatment were compared between the two groups. Results: The objective response rate of the observation group (62.26%) was higher than that of the control group (42.31%), with a statistically significant difference (P < 0.05). After treatment, both groups showed reduced scores on the Numeric Rating Scale (NRS) for pain intensity and TCM syndrome scores, with the observation group showing lower values than the control group, and the differences were statistically significant (P < 0.05). After treatment, the serum levels of interleukin-6 (IL-6) and C-reactive protein (CRP) in both groups decreased, with the observation group showing lower levels than the control group, and the differences were statistically significant (P < 0.05). The total incidence of adverse reactions in the observation group (5.66%) was lower than that in the control group (19.23%), with a statistically significant difference (P < 0.05). After treatment, the serum levels of carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and soluble fragment of cytokeratin 19 (CYFRA 21-1) in both groups decreased, with the observation group showing lower levels than the control group, and the differences were statistically significant (P < 0.05). Conclusion: Shenqi Fuzheng Liquid as adjunctive therapy for patients with lung cancer can effectively control the body's inflammatory response, alleviate cancer pain, reduce serum tumor marker levels, improve clinical outcomes, and relieve symptoms while reducing the occurrence of adverse reactions.